AxoGen (AXGN)
(Delayed Data from NSDQ)
$14.69 USD
+0.40 (2.80%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $14.69 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.69 USD
+0.40 (2.80%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $14.69 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum B VGM
Zacks News
AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cousins Properties' (CUZ) Heights Union Buyout Fails to Drive Stock
by Zacks Equity Research
The acquisition of Heights Union is in line with Cousins Properties' (CUZ) efforts to enhance its portfolio quality with trophy assets.
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and 3.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Stock Jumps 12.5%: Will It Continue to Soar?
by Zacks Equity Research
AxoGen (AXGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 52.94% and 8.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 130.77% and 11.06%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 40.00% and 5.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: AxoGen (AXGN) Q1 Earnings Expected to Decline
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 30.00% and 1.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AxoGen (AXGN) Q3 Earnings Expected to Decline
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 23.08% and -0.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of -7.14% and 4.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AxoGen (AXGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.
What's in Store for Humana (HUM) Stock in Q4 Earnings?
by Zacks Equity Research
Higher enrollment and strong segmental results are expected to help Humana (HUM) in fourth-quarter earnings.
AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 0.00% and 0.56%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DWAS
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q1
by Zacks Equity Research
Dr Reddy's (RDY) surpasses both earnings and sales year over year in the first quarter of fiscal 2019.
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for DWAS